Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
European journal of cancer (Oxford, England : 1990).
Times cited: 10
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
Times cited: 27